SCF<sup>FBXO22</sup> targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31138683.
- Also identified by DOI 10.1073/pnas.1820990116 and PMC identifier 6575577.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Human homolog of mouse double minute 2 (HDM2) is an oncogene frequently overexpressed in cancers with poor prognosis, but mechanisms of controlling its abundance remain elusive. In an unbiased biochemical search, we discovered <u>S</u>kp1-<u>C</u>ullin 1-<u>F</u>BXO22-ROC1 (SCF<sup>FBXO22</sup>) as the most dominating HDM2 E3 ubiquitin ligase from human proteome. The results of protein decay rate analysis, ubiquitination, siRNA-mediated silencing, and coimmunoprecipitation experiments support a hypothesis that FBXO22 targets cellular HDM2 for ubiquitin-dependent degradation. In human breast cancer cells, FBXO22 knockdown (KD) increased cell invasiveness, which was driven by elevated levels of HDM2. Moreover, mouse 4T1 breast tumor model studies revealed that FBXO22 KD led to a significant increase of breast tumor cell metastasis to the lung. Finally, low FBXO22 expression is correlated with worse survival and high HDM2 expression in human breast cancer. Altogether, these findings suggest that SCF<sup>FBXO22</sup> targets HDM2 for degradation and possesses inhibitory effects against breast cancer tumor cell invasion and metastasis.
Medical subject headings
- Breast Neoplasms
- Cell Movement
- F-Box Proteins
- Neoplasm Invasiveness
- Neoplasm Metastasis
- Proto-Oncogene Proteins c-mdm2
- Receptors, Cytoplasmic and Nuclear